Kelly Fitzpatrick, MD
Medical Oncology · Neptune, NJNPI 1083860944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $794, more than ten times the $23 reported in 2020. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.
Across 53 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$165
- GSK$149
- E.r. Squibb & Sons, L.L.C.$148
- Geron Corporation$115
- Astellas Pharma US Inc$105
- Amgen$88
- plus $553 from 17 others
Across 36 payments — averaging $11,995 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$432K
What the payments were for
- Food & beverage$1,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 7 | $165 |
| GSK | 4 | $149 |
| E.r. Squibb & Sons, L.L.C. | 2 | $148 |
| Geron Corporation | 1 | $115 |
| Astellas Pharma US Inc | 5 | $105 |
| Amgen | 4 | $88 |
| AbbVie | 3 | $73 |
| Melinta Therapeutics, LLC | 4 | $68 |
| Angiodynamics, Inc. | 3 | $65 |
| Novartis | 2 | $54 |
| Bristol Myers Squibb | 3 | $44 |
| Incyte Corporation | 2 | $39 |
| Taiho Oncology, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $28 |
| Sobi, Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| Syndax Pharmaceuticals, Inc. | 1 | $16 |
| ADC Therapeutics America, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Gilead | 1 | $15 |
| Pfizer | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,323 in reported general payments places this provider in the 40th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnuregAzacitidine | 18 | $452,241 |
| InqoviDecitabine/Cedazuridine | 52 | $426,710 |
| XospataGilteritinib Fumarate | 21 | $394,396 |
| JakafiRuxolitinib Phosphate | 34 | $356,331 |
| VenclextaVenetoclax | 87 | $325,787 |
| CresembaIsavuconazonium Sulfate | 20 | $121,309 |
| SprycelDasatinib | 11 | $107,635 |
| Posaconazole | 69 | $87,246 |
| EliquisApixaban | 37 | $24,659 |
| Tretinoin | 12 | $21,829 |
| Atovaquone | 26 | $13,591 |
| Vancomycin Hcl | 11 | $5,964 |
| Ciprofloxacin Hcl | 84 | $2,605 |
| ValacyclovirValacyclovir Hcl | 25 | $1,978 |
| Acyclovir | 108 | $1,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Onureg, Sprycel | $148 | $559,87629 claims |
| Astellas Pharma US IncXospata, Cresemba | $105 | $515,70541 claims |
| Taiho Oncology, Inc.Inqovi | $38 | $426,71052 claims |
| Incyte CorporationJakafi | $39 | $356,33134 claims |
| AbbVieVenclexta | $73 | $325,78787 claims |
| PfizerEliquis | $14 | $24,65937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Neptune
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.